Search

Your search keyword '"Verzenio (Medication)"' showing total 387 results
Start Over Descriptor "Verzenio (Medication)"
387 results on '"Verzenio (Medication)"'

101. Event Brief of Q3 2021 Eli Lilly and Co Earnings Call - Final

Subjects
Eli Lilly and Co., Pharmaceutical industry, Business, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Semglee (Medication), Emgality (Medication)
Abstract

CORPORATE PARTICIPANTS . Anat Ashkenazi - Eli Lilly and Company,Senior VP & CFO . Anne E. White - Eli Lilly and Company,Senior VP & President of Lilly Neuroscience . Daniel [...]

Published
2021

102. Q3 2021 Eli Lilly and Co Earnings Call - Final

Subjects
Eli Lilly and Co., Pharmaceutical industry, Business, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Semglee (Medication), Emgality (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by and welcome to the Lilly Quarter 3 2021 Earnings Call. (Operator Instructions) As a reminder, today's conference is being recorded. [...]

Published
2021

103. Eli Lilly's Verzenio 'clear winner' over Pfizer's Ibrance, says Morgan Stanley

Subjects
Morgan Stanley, Pfizer Inc., Eli Lilly and Co., Periodical publishing, Securities industry, Pharmaceutical industry, Securities industry, Business, News, opinion and commentary, Verzenio (Medication), Ibrance (Medication)
Abstract

After Eli Lilly (LLY) presented detailed data on its monarchE study at ESMO and in a published journal, Morgan Stanley analyst David Risinger noted that Verzenio demonstrated a 'compelling' 25% [...]

Published
2020

104. Eli Lilly to present new data from cancer research pipeline at ESMO

Subjects
Eli Lilly and Co., Cancer, Cancer research, Pharmaceutical industry, Business, News, opinion and commentary, Verzenio (Medication)
Abstract

Data from 20 studies across Eli Lilly's oncology product portfolio will be presented at the European Society for Medical Oncology, or ESMO, virtual congress, September 19-21. The data include results [...]

Published
2020

105. Eli Lilly price target raised to $190 from $175 at JPMorgan

Subjects
Eli Lilly and Co., Pharmaceutical industry, Business, News, opinion and commentary, Verzenio (Medication)
Abstract

JPMorgan analyst Chris Schott raised the firm's price target on Eli Lilly to $190 from $175 and keeps an Overweight rating on the shares after positive data for Verzenio in [...]

Published
2020

106. Eli Lilly says Verzenio with standard adjuvant ET therapy met primary endpoint

Subjects
Eli Lilly and Co., Pharmaceutical industry -- Standards, Business, News, opinion and commentary, Verzenio (Medication)
Abstract

Eli Lilly announced Verzenio in combination with standard adjuvant endocrine therapy, or ET, has met the primary endpoint of invasive disease-free survival, or IDFS, significantly decreasing the risk of breast [...]

Published
2020

107. Eli Lilly soars 15% after its breast cancer drug shows efficacy where a treatment from Pfizer failed

Subjects
Pfizer Inc., Eli Lilly and Co., Antineoplastic agents, Breast cancer -- Drug therapy, Pharmaceutical industry, Antimitotic agents, Consumer news and advice, General interest, Verzenio (Medication), Ibrance (Medication)
Abstract

Eli Lilly soared 14% on Tuesday after it announced that its breast cancer drug Verzenio was successful in meeting its primary endpoint in a Phase 3 trial. Verzenio was successful [...]

Published
2020

108. Guggenheim upgrades Eli Lilly to Buy after 'transformational' breast cancer data

Subjects
Pfizer Inc., Eli Lilly and Co., Pharmaceutical industry, Breast cancer, Business, News, opinion and commentary, Verzenio (Medication)
Abstract

As previously reported, Guggenheim analyst Seamus Fernandez upgraded Eli Lilly to Buy from Neutral with an $182 price target following this morning's positive monarchE study results. Earlier, Eli Lilly announced [...]

Published
2020

109. Lilly trial has higher risk and reward after Pfizer failure, says Morgan Stanley

Subjects
Morgan Stanley, Pfizer Inc., Eli Lilly and Co., Securities industry, Pharmaceutical industry, Breast cancer, Surgery, Setting (Literature), Cancer metastasis, Securities industry, Business, News, opinion and commentary, Verzenio (Medication), Ibrance (Medication)
Abstract

Morgan Stanley analyst David Risinger said the failure of Pfizer's (PFE) early stage adjuvant, after-surgery, breast cancer trial with Ibrance, PALLAS, at an interim analysis may suggest incremental risk for [...]

Published
2020

110. Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium

Subjects
Eli Lilly and Co. -- Conferences, meetings and seminars, Oncology, Experimental -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Estrogen -- Conferences, meetings and seminars, Breast cancer -- Conferences, meetings and seminars, Cancer -- Research, Fulvestrant -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, General interest, News, opinion and commentary, Verzenio (Medication)
Abstract

United States: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced that study investigators will present data from its breast cancer [...]

Published
2022

111. Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium

Subjects
Eli Lilly and Co. -- Conferences, meetings and seminars, Oncology, Experimental -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Estrogen -- Conferences, meetings and seminars, Breast cancer -- Development and progression -- Conferences, meetings and seminars, Cancer -- Research, Fulvestrant -- Conferences, meetings and seminars, Business, News, opinion and commentary, Verzenio (Medication)
Abstract

INDIANAPOLIS, Nov. 21, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that study investigators will present data from its breast cancer portfolio and pipeline at the 2022 [...]

Published
2022

112. Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress

Subjects
United States. Food and Drug Administration -- Officials and employees, Boehringer Ingelheim GmbH -- Company sales and earnings -- Officials and employees, Eli Lilly and Co. -- Officials and employees -- Company sales and earnings, Pipe lines, Pharmaceutical industry -- Company sales and earnings -- Officials and employees, Company earnings/profit, Business, News, opinion and commentary, Olumiant (Medication), Jardiance (Medication), Verzenio (Medication), Mounjaro (Medication)
Abstract

Lilly's revenue in Q3 2022 increased 2%, or 7% on a constant currency basis, primarily driven by volume growth of key growth products, partially offset by lower realized prices and [...]

Published
2022

113. Lilly Announces Details of Presentations at ESMO Congress 2022

Subjects
Eli Lilly and Co., Fulvestrant, Pharmaceutical industry, General interest, News, opinion and commentary, Verzenio (Medication), Retevmo (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company ( NYSE: LLY) today announced that data from studies of Verzenio(r) (abemaciclib) and Retevmo(r) (selpercatinib) [...]

Published
2022

114. Q2 2021 Eli Lilly and Co Earnings Call - Final

Subjects
Eli Lilly and Co., Pharmaceutical industry, Business, Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Verzenio (Medication), Taltz (Medication), Semglee (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by, and welcome to Lilly's Q2 Earnings Call. (Operator Instructions) As a reminder, today's conference is being recorded. I would now [...]

Published
2021

115. Event Brief of Q2 2021 Eli Lilly and Co Earnings Call - Final

Subjects
United States. Centers for Medicare and Medicaid Services, Eli Lilly and Co., Pharmaceutical industry, Business, Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Verzenio (Medication), Taltz (Medication), Semglee (Medication)
Abstract

CORPORATE PARTICIPANTS . Anat Ashkenazi - Eli Lilly and Company,Senior VP & CFO . Anne E. White - Eli Lilly and Company,Senior VP & President of Lilly Oncology . Daniel [...]

Published
2021

116. Eli Lilly and Co at Guggenheim Biopharma's Next Decade Virtual Conference - Final

Subjects
Eli Lilly and Co. -- Conferences, meetings and seminars, Biological products industry -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business, Verzenio (Medication)
Abstract

Presentation SEAMUS CHRISTOPHER FERNANDEZ, SENIOR ANALYST OF GLOBAL PHARMACEUTICALS, GUGGENHEIM SECURITIES, LLC, RESEARCH DIVISION: Okay. It looks like we are on to the second discussion today. Earlier, we had Novo [...]

Published
2021

117. Eli Lilly and Co at Goldman Sachs Global Healthcare Conference (Virtual) - Final

Subjects
The Goldman Sachs Group Inc. -- Conferences, meetings and seminars, Eli Lilly and Co. -- Conferences, meetings and seminars, Investment banks -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business, Imbruvica (Medication), Verzenio (Medication)
Abstract

Presentation TERENCE C. FLYNN, MD, GOLDMAN SACHS GROUP, INC., RESEARCH DIVISION: Great. Good morning, everybody. I'm Terence Flynn, the U.S. biopharma analyst at Goldman Sachs, and we're very pleased to [...]

Published
2021

118. Event Brief of Q1 2021 Eli Lilly and Co Earnings Call - Final

Subjects
Eli Lilly and Co., Pharmaceutical industry, Business, Olumiant (Medication), Trulicity (Medication), Verzenio (Medication), Taltz (Medication)
Abstract

CORPORATE PARTICIPANTS . Anat Ashkenazi - Eli Lilly and Company,Senior VP & CFO . Anne E. White - Eli Lilly and Company,Senior VP & President of Lilly Oncology . Daniel [...]

Published
2021

119. Q1 2021 Eli Lilly and Co Earnings Call - Final

Subjects
Eli Lilly and Co., Pharmaceutical industry, Business, Olumiant (Medication), Trulicity (Medication), Verzenio (Medication), Taltz (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q1 2021 Earnings Conference Call. (Operator Instructions) As a reminder, this conference is being recorded. [...]

Published
2021

120. Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements

Subjects
Eli Lilly and Co. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Olumiant (Medication), Jardiance (Medication), Verzenio (Medication), Mounjaro (Medication), Humalog (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced its financial results for the second quarter of 2022. 'We had [...]

Published
2022

121. Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements

Subjects
United States. Food and Drug Administration, Boehringer Ingelheim GmbH -- Company sales and earnings, Eli Lilly and Co. -- Company sales and earnings, Pipe lines, Viral antibodies, Antibodies, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, News, opinion and commentary, Olumiant (Medication), Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Cialis (Medication), Mounjaro (Medication), Taltz (Medication)
Abstract

Lilly's revenue in Q2 2022 decreased 4%. On a constant currency basis, revenue decreased 1% as lower realized prices and lower Alimta revenue following the entry of generics more than [...]

Published
2022

122. Switzerland : New CDK4|6i data at ASCO reinforce Novartis Kisqali as only drug in class with consistently proven overall survival benefit in HR+|HER2- metastatic breast cancer

Subjects
Postmenopausal women -- Patient outcomes -- Drug therapy, Metastasis -- Patient outcomes -- Drug therapy, Breast cancer -- Drug therapy -- Patient outcomes, Fulvestrant -- Analysis, Business, international, Verzenio (Medication), Kisqali (Medication)
Abstract

Kisqali is the only CDK4/6 inhibitor with consistent overall survival (OS) benefit seen across all three Phase III trials, with the longest median OS benefit ever reported for HR+/HER2- mBC1-10 [...]

Published
2022

123. Eli Lilly and Co at Guggenheim Partners Healthcare Talks Oncology Days - Final

Subjects
Eli Lilly and Co., Loxo Oncology Inc., Fulvestrant, Pharmaceutical industry, Business, Verzenio (Medication), Retevmo (Medication)
Abstract

Presentation SEAMUS CHRISTOPHER FERNANDEZ, SENIOR ANALYST OF GLOBAL PHARMACEUTICALS, GUGGENHEIM SECURITIES, LLC, RESEARCH DIVISION: All right. Good morning, everyone. I believe we are now live. And this is the second [...]

Published
2021

124. Event Brief of Q4 2020 Eli Lilly and Co Earnings Call - Final

Subjects
Eli Lilly and Co. -- Officials and employees, Pharmaceutical industry -- Officials and employees, Business, Trulicity (Medication), Verzenio (Medication), Taltz (Medication)
Abstract

CORPORATE PARTICIPANTS . Anne E. White - Eli Lilly and Company,Senior VP & President of Lilly Oncology . Daniel M. Skovronsky - Eli Lilly and Company,Senior VP, Chief Scientific Officer [...]

Published
2021

125. Q4 2020 Eli Lilly and Co Earnings Call - Final

Subjects
Eli Lilly and Co. -- Officials and employees, Pharmaceutical industry -- Officials and employees, Business, Trulicity (Medication), Verzenio (Medication), Taltz (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q4 2020 Earnings Call. (Operator Instructions) As a reminder, this conference is being recorded. I [...]

Published
2021

126. Lilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Subjects
Eli Lilly and Co. -- Conferences, meetings and seminars, Oncology, Experimental -- Conferences, meetings and seminars, Trade and professional associations -- Conferences, meetings and seminars, Estrogen -- Conferences, meetings and seminars, Cancer -- Research, Pharmaceutical industry -- Conferences, meetings and seminars, General interest, News, opinion and commentary, Verzenio (Medication), Retevmo (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the [...]

Published
2022

127. Lilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Subjects
Eli Lilly and Co. -- Conferences, meetings and seminars, Oncology, Experimental -- Conferences, meetings and seminars, Trade and professional associations -- Conferences, meetings and seminars, Estrogen -- Conferences, meetings and seminars, Cancer -- Research, Fulvestrant -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business, News, opinion and commentary, Verzenio (Medication), Retevmo (Medication)
Abstract

INDIANAPOLIS, May 26, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the 2022 American Society of Clinical [...]

Published
2022

128. Solid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022

Subjects
United States. Food and Drug Administration, Boehringer Ingelheim GmbH -- Company sales and earnings, Eli Lilly and Co. -- Company sales and earnings, Viral antibodies, Antibodies, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, News, opinion and commentary, Olumiant (Medication), Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Cyramza (Medication), Retevmo (Medication), Taltz (Medication), Emgality (Medication)
Abstract

Lilly's revenue growth in Q1 2022 increased 15%, driven by volume growth of 20%. Excluding revenue from COVID-19 antibodies and Alimta, Q1 2022 revenue grew 10%. Outside of revenue from [...]

Published
2022

129. Event Brief of Eli Lilly and Co 2021 Guidance Call - Final

Subjects
Eli Lilly and Co., Loxo Oncology Inc., Executives, Type 2 diabetes, Pharmaceutical industry, Business, Olumiant (Medication), Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Taltz (Medication)
Abstract

CORPORATE PARTICIPANTS . Daniel M. Skovronsky - Eli Lilly and Company,Senior VP, Chief Scientific Officer & President of Lilly Research Labs . David A. Ricks - Eli Lilly and Company,Chairman, [...]

Published
2020

130. Eli Lilly and Co 2021 Guidance Call - Final

Subjects
Eli Lilly and Co., Loxo Oncology Inc., Chief financial officers, Type 2 diabetes, Pharmaceutical industry, Business, Olumiant (Medication), Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Taltz (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by, and welcome to the Lilly 2021 Guidance Call. (Operator Instructions) As a reminder, today's conference call is being recorded. I [...]

Published
2020

131. Event Brief of Q3 2020 Eli Lilly and Co Earnings Call - Final

Subjects
United States. Food and Drug Administration, Eli Lilly and Co., Pharmaceutical industry, Business, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication)
Abstract

CORPORATE PARTICIPANTS . Anne E. White - Eli Lilly and Company,Senior VP & President of Lilly Oncology . Daniel M. Skovronsky - Eli Lilly and Company,Senior VP, Chief Scientific Officer [...]

Published
2020

132. Q3 2020 Eli Lilly and Co Earnings Call - Final

Subjects
United States. Food and Drug Administration, Eli Lilly and Co., Pharmaceutical industry, Business, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by, and welcome to Lilly's Q3 2020 Earnings Call. (Operator Instructions) And as a reminder, your conference is being recorded. I [...]

Published
2020

133. Eli Lilly and Co to Discuss ESMO 2020 Presentations Conference Call - Final

Subjects
Pfizer Inc., Eli Lilly and Co., Vice presidents (Organizations), Fulvestrant, Pharmaceutical industry, Medical schools, Business, Verzenio (Medication), Ibrance (Medication), Retevmo (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for your patience in holding, and welcome to the Lilly Oncology Update. (Operator Instructions) Just a brief reminder, today's conference is being recorded. [...]

Published
2020

134. Event Brief of Q2 2020 Eli Lilly and Co Earnings Call - Final

Subjects
Eli Lilly and Co., Pharmaceutical industry, Business, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Retevmo (Medication), Taltz (Medication), Emgality (Medication)
Abstract

CORPORATE PARTICIPANTS . Anne E. White - Eli Lilly and Company,Senior VP & President of Lilly Oncology . Daniel M. Skovronsky - Eli Lilly and Company,Senior VP, Chief Scientific Officer [...]

Published
2020

135. Q2 2020 Eli Lilly and Co Earnings Call - Final

Subjects
Eli Lilly and Co., Pharmaceutical industry, Business, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Retevmo (Medication), Taltz (Medication), Emgality (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2020 Earnings Call. (Operator Instructions) As a reminder, today's call is being recorded. I [...]

Published
2020

136. Eli Lilly and Co at Goldman Sachs Global Healthcare Conference (Virtual) - Final

Subjects
The Goldman Sachs Group Inc. -- Conferences, meetings and seminars -- Forecasts and trends, Eli Lilly and Co. -- Conferences, meetings and seminars -- Forecasts and trends, Conferences and conventions -- Conferences, meetings and seminars, Investment banks -- Conferences, meetings and seminars -- Forecasts and trends, Pharmaceutical industry -- Forecasts and trends -- Conferences, meetings and seminars, Market trend/market analysis, Business, Trulicity (Medication), Verzenio (Medication)
Abstract

Presentation TERENCE C. FLYNN, MD, GOLDMAN SACHS GROUP INC., RESEARCH DIVISION: Great. Good afternoon, everybody. I'm Terence Flynn, the biopharma analyst at Goldman Sachs. Today, we're very pleased to be [...]

Published
2020

137. Eli Lilly and Co at Goldman Sachs Global Healthcare Conference (Virtual) - Final

Subjects
The Goldman Sachs Group Inc. -- Conferences, meetings and seminars -- Forecasts and trends, Eli Lilly and Co. -- Conferences, meetings and seminars -- Forecasts and trends, Conferences and conventions -- Conferences, meetings and seminars, Baricitinib -- Conferences, meetings and seminars, Investment banks -- Conferences, meetings and seminars -- Forecasts and trends, Pharmaceutical industry -- Forecasts and trends -- Conferences, meetings and seminars, COVID-19 -- Conferences, meetings and seminars, Market trend/market analysis, Business, Trulicity (Medication), Verzenio (Medication)
Abstract

Presentation TERENCE C. FLYNN, MD, GOLDMAN SACHS GROUP INC., RESEARCH DIVISION: Great. Good afternoon, everybody. I'm Terence Flynn, a biopharma analyst at Goldman Sachs. Today, we're very pleased to be [...]

Published
2020

138. Eli Lilly says Verzenio 'significantly extends life for women in MONARCH 2 study

Subjects
Eli Lilly and Co., Fulvestrant, Pharmaceutical industry, Epidermal growth factors, Breast cancer, Hormones, Postmenopausal women, Conferences and conventions, Clinical trials, Cancer metastasis, Business, News, opinion and commentary, Verzenio (Medication)
Abstract

Eli Lilly and Company announced that Verzenio in combination with fulvestrant significantly extended life by a median of 9.4 months in women with hormone receptor-positive, human epidermal growth factor receptor [...]

Published
2019

139. Phase 3 MONARCH 2 study shows Verzenio significantly extends life by a median of 9.4 months for women with HR+, HER2- ad

Subjects
Eli Lilly and Co. -- Product development, Clinical trials, Fulvestrant -- Research -- Product development, Pharmaceutical industry -- Product development, Women, Abemaciclib -- Research -- Product development, Cancer metastasis -- Research, Epidermal growth factors, Breast cancer, Hormones, Postmenopausal women, Conferences and conventions, Cancer, Pharmaceuticals and cosmetics industries, Verzenio (Medication)
Abstract

Eli Lilly and Company announced Verzenio (abemaciclib) in combination with fulvestrant significantly extended life by a median of 9.4 months in women with hormone receptor-positive (HR+), human epidermal growth factor [...]

Published
2019

140. Eli Lilly announces results from Phase 3 MONARCH 2 clinical trial

Subjects
Eli Lilly and Co. -- Company sales and earnings -- Product development, Clinical trials, Fulvestrant -- Product development, Pharmaceutical industry -- Company sales and earnings -- Product development, Epidermal growth factors, Breast cancer, Hormones, Postmenopausal women, Cancer, Cancer metastasis, Company earnings/profit, Business, News, opinion and commentary, Verzenio (Medication)
Abstract

Eli Lilly announced Verzenio in combination with fulvestrant significantly extended life by a median of 9.4 months in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or [...]

Published
2019

141. Eli Lilly announces Verzenio demonstrates improvement in overall survival

Subjects
Eli Lilly and Co., Fulvestrant -- Analysis, Pharmaceutical industry -- Analysis, Epidermal growth factors, Breast cancer, Hormones, Postmenopausal women, Clinical trials, Cancer metastasis, Women, Business, News, opinion and commentary, Verzenio (Medication)
Abstract

Eli Lilly announced that Verzenio demonstrated a statistically significant improvement in overall survival in the Phase 3 MONARCH 2 clinical trial. These results were from a pre-planned interim analysis. MONARCH [...]

Published
2019

142. Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patients

Subjects
United States. Food and Drug Administration, Boehringer Ingelheim GmbH -- Company sales and earnings, Eli Lilly and Co. -- Company sales and earnings, Pipe lines, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cyramza (Medication), Retevmo (Medication), Taltz (Medication), Humalog (Medication), Emgality (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) announced financial results for the fourth quarter and full year of 2021 today. [...]

Published
2022

144. Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patients

Subjects
United States. Food and Drug Administration, Boehringer Ingelheim GmbH -- Company sales and earnings, Eli Lilly and Co. -- Company sales and earnings, Pipe lines, Viral antibodies, Antibodies, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, News, opinion and commentary, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cyramza (Medication), Retevmo (Medication), Taltz (Medication), Humalog (Medication), Emgality (Medication)
Abstract

- Revenue in the fourth quarter of 2021 increased 8 percent, driven by volume growth of 11 percent. Excluding COVID-19 antibodies, fourth-quarter 2021 revenue grew 6 percent. - Full-year 2021 [...]

Published
2022

145. Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential

Subjects
United States. Food and Drug Administration, Eli Lilly and Co. -- Company sales and earnings, Pipe lines, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Olumiant (Medication), Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Retevmo (Medication)
Abstract

United States: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) announced financial results for the third quarter of 2021 today. 'Lilly demonstrated [...]

Published
2021

146. Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential

Subjects
United States. Food and Drug Administration, Eli Lilly and Co. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, News, opinion and commentary, Olumiant (Medication), Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Cyramza (Medication), Retevmo (Medication), Taltz (Medication), Emgality (Medication)
Abstract

- Revenue in the third quarter of 2021 increased 18 percent, driven by volume growth of 17 percent. When excluding revenue from COVID-19 therapies, revenue growth was 11 percent in [...]

Published
2021

147. Australia : Breast cancer treatment expanded on the Pharmaceutical Benefits Scheme

Subjects
Antineoplastic agents, Cancer -- Care and treatment, Breast cancer -- Drug therapy, Antimitotic agents, Business, international, Verzenio (Medication)
Abstract

The Morrison Government is helping improve access to an important treatment for Australians battling a form of breast cancer. From 1 November 2021, the Pharmaceutical Benefits Scheme (PBS) listing of [...]

Published
2021

150. Lilly to Present New Data from Oncology Portfolio at ESMO Congress

Subjects
Eli Lilly and Co., Fulvestrant, Pharmaceutical industry, General interest, News, opinion and commentary, Verzenio (Medication), Cyramza (Medication), Retevmo (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: New data from various studies of Eli Lilly and Company's (NYSE: LLY) Verzenio(r) (abemaciclib), Retevmo(r) (selpercatinib) and CYRAMZA(r) (ramucirumab) [...]

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results